Incarda Therapeutics, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2021-09-09
Last Posted Date
2023-10-30
Lead Sponsor
InCarda Therapeutics, Inc.
Target Recruit Count
54
Registration Number
NCT05039359
Locations
🇵🇱

Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Toruń, Poland

🇺🇸

Bridgeport Hospital, Bridgeport, Connecticut, United States

🇺🇸

University of Cincinnati College of Medicine, Cincinnati, Ohio, United States

and more 37 locations

INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)

First Posted Date
2018-05-29
Last Posted Date
2024-05-14
Lead Sponsor
InCarda Therapeutics, Inc.
Target Recruit Count
176
Registration Number
NCT03539302
Locations
🇧🇪

Imelda, Bonheiden, Belgium

🇳🇱

OLVG, Amsterdam, Netherlands

🇳🇱

Deventer Ziekenhuis, Deventer, Netherlands

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath